Frontpage Hero

Because we care, we need to act

Read more here

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.

Click here to go to the on-line version of the annual report

Annual General Meeting 2018

The Annual General Meeting will be held on Wednesday, May 9, 2018 at 15:00.at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
More information about the AGM is found here.

Press releases

Sobi™ publishes the report for the first quarter 2018

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the first quarter 2018. Total revenues grew 41 per cent compared to Q1 2017 and amounted to SEK 1,964 M. EBITA was SEK 771 M, an increase of 90 per cent and gross margin amounted to 72 per cent...

04/26/2018 - 08:00
Invitation – Presentation of Sobi’s Q1 2018 results

On 26 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day...

04/19/2018 - 10:00
Sobi publishes 2017 Annual and Sustainability Report

Swedish Orphan Biovitrum AB (publ) (Sobi™) publishes its 2017 Annual and Sustainability Report today on World Haemophilia Day. The report summarises our business and financial highlights for 2017 as well as our enhanced sustainability initiative.

“We have successfully...

04/17/2018 - 09:00
Kineret® (anakinra) approved in the EU for the treatment of Still’s disease

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved an extension of the indication for Kineret (anakinra) to include the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset...

04/11/2018 - 09:00
Read more
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden
All contacts